Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
OBJECTIVE
The sequence variability in the protease and in the 5 Gag cleavage sites (CS) were explored to look for eventual associations between the mutations. Moreover, we have evaluated associations between the Gag region sequence and the virological response to Protease Inhibitors (PI).


METHODS
The protease and the 5 Gag CS sequences from 98 PI-experienced patients were sequenced and compared to the HXB2 reference sequence. Sixty patients, treated by Saquinavir plus Ritonavir, were studied to evaluate the clinical impact of the Gag region variability.


RESULTS
The relationship between 63 protease mutations and 21 Gag CS mutations were explored. Two patterns of mutations in the protease were identified: (M46I/L, I54V, V82A/T/F) was associated to the A431V and (K20I/R/M, L89M/I) to the S373Q and L449P. None of the Gag CS mutations resulting from PI treatment was associated to the virological response to SQV/r. On the other hand, the S373P mutation had a negative impact on the virological response that remained statistically significant in a multivariate analysis after adjustment on the number of PI resistance mutations.


CONCLUSIONS
These results evoke the pertinence to introduce some mutations found in the Gag CS in the algorithms used for the interpretation of resistance testing.
Malet
Isabelle
I
Laboratoire de Virologie (bâtiment CERVI), Hôpital Pitié-Salpêtrière, EA 2387, Université Pierre et Marie Curie (Paris 6), Paris, France. isabelle.malet@psl.aphp.fr <isabelle.malet@psl.aphp.fr>
Roquebert
Bénédicte
B
Dalban
Cécile
C
Wirden
Marc
M
Amellal
Bahia
B
Agher
Rachid
R
Simon
Anne
A
Katlama
Christine
C
Costagliola
Dominique
D
Calvez
Vincent
V
Marcelin
Anne-Geneviève
AG
D000595:Amino Acid Sequence; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D001665:Binding Sites / Q000235:genetics; D024882:Drug Resistance, Viral; D015683:Gene Products, gag / Q000737:chemistry* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D019438:Ritonavir / Q000494:pharmacology / Q000627:therapeutic use; D019258:Saquinavir / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D015683:Gene Products, gag; D017320:HIV Protease Inhibitors; D016333:HIV Protease; D019258:Saquinavir; D019438:Ritonavir